Skip to content

Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-amputation in PAD Patients

Wound Imaging System to Gather Clinical References: Collection of Clinical References Images for the Second Generation DeepView Wound Imaging System

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03611361
Acronym
WISCR
Enrollment
55
Registered
2018-08-02
Start date
2015-11-18
Completion date
2020-12-31
Last updated
2024-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Amputation Wound, Peripheral Arterial Disease

Keywords

peripheral arterial disease, re-amputation, optical imaging, Computer Assisted Detection (CADe)

Brief summary

This is a proof-of-concept study to collect images to train a CADe algorithm to predict the correct level of amputation in individuals scheduled for amputation secondary to PAD.

Detailed description

SpectralMD has developed an imaging device (DeepView), which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a CADe algorithm to categorize microvascular blood flow and provide a quantitative assessment to aid in selecting the appropriate amputation site. The investigators intend to gather data to train the CADe algorithm to predict ultimate healing status of tissue in the lower extremities of individuals suffering from peripheral arterial disease (PAD). The investigators will demonstrate the feasibility of using such an algorithm to accurately predict the location and extent of small vessel disease prior to amputation. Eventually, the invesitgators expect the DeepView to reduce the rate of re-amputation in patients with peripheral arterial disease if used for routine assessment of patients prior to amputation. The aims of the study are as follows: * Evaluate performance of a Computer Assisted Detection (CADe) algorithm trained to assist selecting the level-of-amputation in patients with PAD. * Identify multispectral signatures that are strongly predictive of viable skin tissue at proposed amputation sites. * Create a representative database for training the CADe algorithm.

Interventions

DEVICESpectralMD DeepView Wound Imaging System 2.0

The DeepView is an imaging device which simultaneously performs multispectral imaging (MSI) measurements across the visible and infrared spectrum to obtain a quantitative tissue viability assessment. These optical measurements are integrated using a machine learning (ML) algorithm to categorize microvascular blood flow and provide a quantitative assessment for selection of tissue healing.

Sponsors

Baylor Research Institute
CollaboratorOTHER
SpectralMD
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Patient must require amputation on a limb secondary to PAD, defined as arterial insufficiency due to atherosclerosis based on one or more of the following assessments: * Ankle brachial index; * Duplex ultrasonography showing clinically significant occlusion; * Arteriography; or * Assessment demonstrating stenosis by arterial calcification. * Able to give informed consent, * Be at least 18 years of age.

Exclusion criteria

* No history of major amputation on the affected limb, or * Life expectancy less than 6 months.

Design outcomes

Primary

MeasureTime frameDescription
Standardized amputation healing assessment30-daysHealing as indicated by: re-epithelialization of tissue within the incision site and no signs of drainage/exudate.

Secondary

MeasureTime frameDescription
Standardized amputation healing assessment90-daysHealing as indicated by: re-epithelialization of tissue within the incision site and no signs of drainage/exudate.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026